CD274 (PD-L1) Polymorphisms as Predictors of Efficacy in First-Line Platinum-Based Chemotherapy for Extensive-Stage Small Cell Lung Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26094245 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Andrés Barba und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, B7-H1 Antigen, Lung Neoplasms, Polymorphism, Single Nucleotide. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
The cornerstone of first-line treatment in extensive-stage small cell lung cancer (ES-SCLC) is platinum- and etoposide-based chemotherapy. Platinum compounds could immunomodulate the tumor microenvironment in addition to their cytotoxic effect. Genetic variation in immune checkpoint (IC) pathways may predict chemotherapy efficacy. Polymorphisms in the IC genes were determined, and their association with survival was analyzed in 78 patients with ES-SCLC treated with chemotherapy. PD-L1 protein expression in tumor tissue was determined. Three variants in CD274 were associated with better median progression-free survival (mPFS): rs2297136 (hazard ratio [HR] 0.52, 95% CI 0.29–0.93; p = 0.03), rs2282055 (HR 0.23, 95% CI 0.09–0.64; p = 0.005), and rs822336 (HR 0.41, 95% CI 0.23–0.73; p = 0.002). CTLA4 rs231775 was also associated with mPFS (HR 0.30, 95% CI 0.14–0.63; p = 0.002). The variants CD274 rs2297136 and CD274 rs822336 were associated with platinum sensitivity (odds ratio [OR] 0.13, 95% CI 0.02–0.70; p = 0.02, and OR 0.08, 95% CI 0.01–0.46; p = 0.005, respectively). CD274 rs2297136 was also associated with better overall survival (p = 0.02), but not after adjustment for covariates. No association was found between CD274 germline variants and PD-L1 tumor expression. Our results suggest that CD274 and CTLA4 variants may be predictive biomarkers for platinum plus etoposide treatment in ES-SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
- Department of Medicine, Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
- Translational Medical Oncology Laboratory, Institut de Recerca Sant Pau (IR Sant Pau), 08041 Barcelona, Spain.
- Department of Pathology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
ORCID-Profile: Laura López-Vilaró, Sergio Martinez-Recio, Margarita Majem, Ivana Sullivan, Juliana Salazar
Zitieren
APA
Barba, A., López-Vilaró, L., Ferre, M., Martinez-Recio, S., Majem, M., Sullivan, I., & Salazar, J. (2025). CD274 (PD-L1) Polymorphisms as Predictors of Efficacy in First-Line Platinum-Based Chemotherapy for Extensive-Stage Small Cell Lung Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094245
Vancouver
Barba A, López-Vilaró L, Ferre M, Martinez-Recio S, Majem M, Sullivan I, et al. CD274 (PD-L1) Polymorphisms as Predictors of Efficacy in First-Line Platinum-Based Chemotherapy for Extensive-Stage Small Cell Lung Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094245
BibTeX
@article{Barba2025,
author = {Barba, Andrés and López-Vilaró, Laura and Ferre, Malena and Martinez-Recio, Sergio and Majem, Margarita and Sullivan, Ivana and Salazar, Juliana},
title = {CD274 (PD-L1) Polymorphisms as Predictors of Efficacy in First-Line Platinum-Based Chemotherapy for Extensive-Stage Small Cell Lung Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26094245}
}
EUVIMED